Kite Pharma (KITE) Tops Q2 EPS by 14c

Kite Pharma (NASDAQ: KITE) reported Q2 EPS of ($0.26), $0.14 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $2.51 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• TTEC Holdings (TTEC) Misses Q2 EPS by 22c ; Offers Guidance
• Verde Clean Fuel (VGAS) Misses Q2 EPS by 4c
• Infinity Natural Resources, Inc. (INR) Tops Q2 EPS by 11c